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Abstract
Due to their size and tailorable physicochemical properties, nanomaterials are an emerging class of 
structures utilized in biomedical applications. There are now many prominent examples of 
nanomaterials being used to improve human health, in areas ranging from imaging and diagnostics 
to therapeutics and regenerative medicine. An overview of these examples reveals several common 
areas of synergy and future challenges. This Nano Focus discusses the current status and future 
potential of promising nanomaterials and their translation from the laboratory to the clinic, by 
highlighting a handful of successful examples.
Advances in medicine in the areas of genomics, proteomics, tissue engineering, and 
regenerative medicine are occurring at a rate that was previously unthinkable. The 
development of new materials resulting from these breakthroughs, such as those that can be 
used to replace blood vessels, to promote tissue growth, to monitor blood glucose levels, or 
to improve the bioavailability of drugs, has been equally rapid and diverse.1,2 One of the 
most exciting frontiers is the development of nanomaterials for biomedical applications.3,4 
Nanomaterials have size-, shape-, and composition-dependent physical, chemical, optical, 
and electronic properties, among others, that can be designed and tuned, and they are 
showing great promise for the diagnosis, treatment, monitoring, and control of disease.5–8 A 
recent survey found that more than 247 nanomaterial-based medical products have been 
approved by the Food and Drug Administration (FDA) and are currently in various stages of 
clinical study.9 Their intended uses range from the treatment of clinically unresectable 
cancers to the preparation of antibacterial hand gels to the regeneration of heart tissue. At the 
same time, common themes emerge when discussing nanomaterials in medicine. Indeed, one 
of the biggest issues is how to translate nanomaterials from the laboratory to the clinic 
effectively.
At the 2015 Materials Research Society (MRS) Spring Meeting in San Francisco (April 6–
10), a special symposium focusing on translational research involving nanomaterials in the 
biomedical field was held. Researchers from all over the world gathered to exchange ideas 
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and to discuss criteria for the selection, development, synthesis, and utilization of 
nanomaterials. In this Nano Focus, we highlight these discussions, which fall into three 
categories: nanotherapeutics, imaging and diagnostics, and tissue regeneration.
Enhancing Efficacy in Nanotherapeutics
Among the numerous nanomaterials explored in therapeutic applications, those often found 
in clinical trials are gold nanoparticles, polymeric nanoparticles, liposomes, and carbon-
based nanomaterials. By sharing expertise across fields, researchers can accelerate the 
utilization of nanomaterials in addressing the challenges faced by traditional therapeutic 
agents.
Since the development of gold-nanoparticle-based spherical nucleic acids (SNAs) in 1996,10 
the Mirkin group at Northwestern University has exploited the properties of this class of 
nanostructures in many areas of biomedicine. Spherical nucleic acids typically consist of a 
nanoparticle core and a highly oriented and densely packed shell of oligonucleotides.11 The 
properties of SNAs emerge from the orientation and arrangement of oligonucleotides on the 
surfaces of these particles. For example, SNAs are taken up into many different cell types 
(over 60 tested to date) at high levels and rates without the need for transfection agents,12 
have high affinities for nucleic acid targets (100 times greater than linear DNA of the same 
sequence),13 and cross both the blood–brain barrier14 and the epidermis15 to reach dificult-
to-target tissues in therapeutic applications. Success in the utilization of SNAs for 
intracellular mRNA detection has led to the commercialization of NanoFlare technology16,17 
under the trade name SmartFlares (Merck Millipore in partnership with AuraSense, LLC, 
Skokie, Illinois), and SNAs have also been applied as agents in gene regulation as 
therapeutics for a host of cancers, including glioblastoma multiforme (an aggressive form of 
brain cancer), and skin disorders, among others. The Mirkin group has made progress in 
using SNAs as immunomodulatory agents.18 Spherical nucleic acids functionalized with 
oligonucleotides displaying toll-like receptor (TLR)-agonist or TLR-antagonist activity were 
shown to be capable of either stimulating or modulating the activity of the immune system, 
respectively. Such structures do so with potencies up to several orders of magnitude higher 
than the conventional linear nucleic acids from which they are composed. This discovery 
paves the way for the development of SNAs as therapeutic cancer vaccines. Mirkin’s 
demonstration of the ability of SNAs to reduce tumor burden and to enhance survival in 
vivo, in mouse models of lymphoma, proved that immunomodulatory SNAs can be directed 
to activate the response of the immune system to destroy tumors in an antigen-specific 
manner (Figure 1).
A fundamental challenge is the delivery of therapeutic molecules inside target cells in the 
body. Nanoparticles have shown immense promise as vehicles for intracellular delivery, with 
proof-of-principle experiments in humans being completed with small interfering RNA 
(siRNA).19 However, there are many barriers to achieving safe and effective delivery 
systems (Figure 2), and potential delivery systems must have multiple functionalities to 
allow in vivo delivery, making the design criteria dificult to define for nanoparticles capable 
of accomplishing intracellular delivery. To accelerate the design and discovery process, the 
Anderson group at the Massachusetts Institute of Technology has pioneered combinatorial 
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methods for nanoparticulate drug delivery. Combinatorial chemical methods have been 
developed to enable the rapid synthesis and characterization of a range of nanoformulations 
based on biodegradable polymers, lipid-like materials, and other materials.20–22 These have 
generated new formulations with particular promise as delivery vehicles for RNA and other 
nucleic acids;23 these formulations have the potential to be used as therapies for many 
diseases, including cancer.24
Furthermore, Shi at Brigham and Women’s Hospital/Harvard Medical School described the 
rational design and development of lipid–polymer hybrid nanoparticle platforms to address 
the bottlenecks faced in the delivery of RNA interference (RNAi) therapeutics, such as 
siRNA.25–27 Specifically, the clinical applications of RNAi in cancer therapy are currently 
hindered by the challenge of achieving the effective systemic in vivo delivery of siRNA to 
tumors. Multiple physiological barriers, such as enzymatic degradation, rapid elimination by 
renal excretion or the mononuclear phagocyte system, and poor cellular uptake and 
endosomal escape, must be overcome. By utilizing hybrid nanoparticles, Shi achieved 
sustained gene silencing, and prolonged circulation of siRNA in the blood for high tumor 
extravasation and accumulation. The successful application of these RNAi nanoparticles to 
validate the therapeutic role of Prohibitin1 in non-small cell lung cancer treatment27 
indicates the significant potential of this platform for the validation of many other potential 
cancer targets and for the clinical development of novel cancer therapies.
Kataoka at the University of Tokyo has pioneered the synthesis and development of 
“polymeric micelle drugs”, which have proven useful for targeting a variety of drugs to 
tissues and organs and to tumors in particular. There has been significant recent progress in 
the clinical development of polymeric micelles loaded with a variety of cytotoxic reagents. 
Notably, five different micellar formulations have already been explored in clinical trials in 
Asia and the United States.28 A version loaded with paclitaxel is in the final stage of a Phase 
III clinical trial in Japan for the treatment of recurrent breast cancer, and it is expected to 
proceed into the application for approval within a year. More recently, Kataoka and 
colleagues have been active in developing a second generation system of polymeric micelles 
installed with ligand moieties at their peripheries. Particularly, cRGD-conjugated polymeric 
micelles were able to cross the blood–brain tumor barrier via a transcytosis mechanism, 
achieving high efficacy in treating intractable orthotopic glioblastoma in animal 
experiments.29 Antibody fragments can also be conjugated to polymeric micelles. In this 
way, higher drug payloads can be achieved without antibody precipitation or impaired 
binding compared to when drugs are directly conjugated to antibody molecules using more 
conventional approaches.30
In 1989, the Kabanov group at the University of North Carolina at Chapel Hill investigated 
the use of polymeric micelles for targeted drug delivery.31 They discovered that Pluronic 
block copolymers can be used in the sensitization of multi-drug-resistant (MDR) cancer and 
cancer stem cells and elucidated the mechanisms responsible for these effects.32 This 
research led to first-in-man polymeric micelle drug candidates for the treatment of cancer 
(SP1049C) that show high efficacy against advanced esophageal cancer in Phase II trials.33 
Recently, they discovered polymeric micelles based on amphiphilic poly(2-oxazoline) 
blocks with unprecedented high capacities for poorly soluble, uncharged drugs (e.g., 
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taxanes) and drug combinations, enabling increasing therapeutic indices compared to current 
drug formulations.34,35
Liposomes are another popular nanomaterial used in preclinical and clinical studies, but it is 
dificult to sustain release from these structures for more than a few days. The Venkatraman 
group at Nanyang Technological University has developed a subconjunctivally injected 
nanoliposome drug delivery system for the long-term (3–5 months) delivery of latanoprost 
that can be used in glaucoma treatment, which went from concept to clinic in less than 5 
years (Figure 3).36,37 Glaucoma is a chronic progressive optic neuropathy that is 
characterized by optic nerve changes and visual field loss. Elevated intraocular pressure 
(IOP) is the main modifiable risk factor. The chronic instillation of daily eye drops to lower 
IOP is the primary treatment of choice, although this regimen requires patient adherence and 
correct performance. Hence, a sustained-delivery system would be a big boon to patients 
with glaucoma. Venkatraman’s group also explored the nanoparticle-mediated sustained 
delivery of siRNA for preventing fibrosis following surgery.38 This method has applications 
in ocular and other types of surgeries/implantations. They have shown sustained efficacy of 
action with a siRNA-incorporated nanoparticle. As shown in the above two examples, the 
premise of their work rests on the ability of nanoparticles to sustain drug/protein/siRNA 
release.
The Chow and Ho groups at the National University of Singapore and the University of 
California, Los Angeles (UCLA), respectively, study nanodiamonds, which are an emerging 
class of carbon-based nanomaterials, due to their advantageous surface characteristics. 
Nanodiamond facets mediate electrostatic properties that have resulted in potent and scalable 
anthracycline drug binding as well as marked enhancements in magnetic resonance imaging 
(MRI) efficiency.39,40 With regard to drug delivery, nanodiamond–doxorubicin compounds 
(NDX) were administered to treat drug-resistant breast and liver tumors in mouse models. 
This study demonstrated the nanodiamond-mediated improvement of drug tolerance; lethal 
dosages of doxorubicin delivered as NDX resulted in the smallest tumors observed 
(compared to saline controls and unmodified drug administration), and all of the treated 
mice survived the full duration of the study.41 The active targeting of triple-negative breast 
tumors in vivo using nanodiamond–epirubicin complexes functionalized with the epidermal 
growth factor receptor (EGFR) antibody resulted in complete tumor regression.42 More 
recently, nanodiamond–anthracycline agents have been used to treat hepatic cancer stem 
cells.43
Toward the further enhancement of the potency and safety of cancer therapies, a prevalent 
challenge in the field of nanomedicine is the ability to move beyond monotherapies toward 
combinatorial cancer treatments. Using phenotypic instead of genotypic profiling to drive 
combinatorial optimization, Ho and colleagues developed a powerful mechanism-
independent engineering optimization platform, termed Feedback System Control.II 
(FSC.II), to identify globally optimized nanodiamond–anthracycline drug combinations 
rapidly.44 FSC.II does not require the use of feedback, and instead, it utilizes a selected set 
of experimental validation assays to formulate phenotypic profiles from which drug 
combinations can rapidly be pin-pointed.
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Mitragotri at the University of California, Santa Barbara, also translated nanomaterials to 
clinical applications (Figure 4). Specifically, he used gold-coated silica nanoparticles for the 
treatment of acne. These 150 nm, poly(ethylene glycol)-coated, silica–gold nanoparticles are 
designed to absorb near-infrared light and produce localized heating. The delivery of these 
nanoparticles into skin is a major hurdle due to the skin’s barrier properties. Mitragotri and 
colleagues showed that these nanoparticles can be delivered deep into the skin’s sebaceous 
glands using low-frequency ultrasound.45 Ultrasound induces cavitation on the surface of the 
skin, which produces microjets and shock waves that open transport pathways into the 
glands.46 Once delivered deep into the glands, the thermal activation of the nanoparticles 
using near-infrared light caused thermolysis and the inactivation of overactive sebaceous 
glands, the underlying pathology of acne. This nanoparticle-based technology provides 
several advantages over standard treatments for acne; for instance, systemic side effects are 
avoided with this treatment.
The Stevens group at the Imperial College of London and collaborators at the Houston 
Methodist Research Institute have recently reported engineering a platform of mesoporous 
silicon nanoneedles for the delivery of nanoparticle and other therapeutic payloads to cells 
and tissues (Figure 5A, B).47,48 This technology could prove transformative in the fields of 
drug delivery, regenerative medicine, and biosensing. The dynamics of the nanoneedle entry 
to the cell and study of the nanoneedle–cell interface have been elucidated and pave the way 
for highly controlled delivery of a range of nanoparticle payloads intracellularly.47 
Furthermore, the nanoneedle array can simultaneously deliver both DNA and siRNA with 
high efficiency (over 90%) and in vivo proved successful in upregulating blood vessel 
formation in muscle by delivery of the VEGF-165 gene (Figure 5C–E).48 The Stevens group 
has also developed several other notable nanomaterials-based technologies, particularly 
enzyme-response nanoparticle systems that have a wide range of important impacts in the 
field of biosensing.8,49,50
From the above discussion of a variety of nanomaterials as nanotherapeutic agents for 
enhancing treatment efficacy, we conclude that successful translation of nanomaterials relies 
on the identification of a clinical problem and innovative ideas to solve it through rational 
design. In addition, more and more versatile nanomaterials are being exploited in emerging 
research themes, areas such as cancer vaccines51 and genome editing.19
Imaging and Diagnostics with High Sensitivity and Selectivity
Besides their use as therapeutic agents, nanomaterials are also being used for imaging and 
diagnostics purposes. The most well-known examples include silica nanoparticles, quantum 
dots, magnetic nanoparticles, and microbubbles. These nanostructures have been used to 
detect small molecules (like H2O2), cells including circulating tumor cells (CTCs), and 
tumor tissues.
The Sun group at Brown University is interested in monitoring cellular H2O2, which is an 
important reactive oxygen species generated via oxygen metabolism; it is actively involved 
in cell signaling and cell growth.52 Unfortunately, its uncontrolled overproduction can cause 
the detrimental oxidation of biomolecules and lead to aging, cancer, and other diseases.53 
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Sun recently developed dumbbell (Au–Fe3O4 and PdPt–Fe3O4) and core/shell (Au/MnO) 
magnetic nanoparticles as sensitive probes for H2O2 detection.54,55 Dumbbell magnetic 
nanoparticles were prepared by the controlled nucleation and growth of Fe3O4 on 
presynthesized noble metal nanoparticles, while the core/shell Au/MnO nanoparticles were 
made by the controlled oxidation of AuMn alloy nanoparticles. Both dumbbell and core/
shell nanoparticles are active for the electrochemical reduction of H2O2 with detection limits 
reaching as low as 5 nM. Highly sensitive electrochemical sensors have been used to 
monitor H2O2 concentration levels released from living cells; tumorigenic cells were found 
to have higher levels of H2O2 than nontumorigenic ones. These composite nanoparticle 
probes can be used in high-sensitivity cancer detection schemes and may also help to 
increase the efficacy of cancer therapies.
The Chen group at the National Institute of Biomedical Imaging and Bioengineering of the 
National Institutes of Health uses nanomaterials as platforms to provide imaging contrast in 
positron emission tomography (PET). In medical imaging, PET can provide a direct, highly 
sensitive, and quantitative readout of organ/tissue targeting efficiency and pharmacokinetics. 
Compared with radiolabeled antibodies, proteins, peptides, and other biologically relevant 
molecules, radiolabeled nanoparticles represent a new frontier in molecular imaging probe 
design because they can combine different imaging modalities and targeting ligands in a 
single vector, synergistically improving the imaging quality.56 However, the applications of 
radiolabeled nanoparticles are based on the premise that the radioisotopes are stably attached 
to the nanomaterials. Chen has developed general rules for selecting appropriate isotopes for 
given types of nanoparticles as well as adjusting the labeling reaction according to specific 
applications. The stability (colloidal and radiochemical) of the radiolabeled nanoparticles as 
well as their biological fate must be assessed; special attention should be paid to labeling 
strategies as they affect the stability of radiolabeled nanoparticles and might cause 
discrepancies in the interpretation of PET data (owing to the distribution of nanoparticles).
Wang’s group at the Chinese Academy of Sciences is interested in creating nano–bio 
interfaces with controllable adhesion properties. The cell-adhesive biointerfaces are based on 
the cooperative effects of multiscale structural matching and molecular recognition.57 They 
explore the relationship between cell-specific adhesion and surface structure (with 
nanowires,21 nanofibers,58 nanofractals,59 and soft nanotubes60). Also, they developed a 
series of biointerfaces with specific recognition and stimuli-responsive capture and release 
properties (i.e., temperature,61 electric,59 enzymatic,21 and pH62). They have made progress 
in the isolation of viable rare CTCs from the blood via their designed cell-adhesive 
biointerfaces and developed adhesion-based CTC isolation approaches as cancer diagnostics 
with high efficiencies (>97%).63 In particular, these biointerfaces with controlled cell 
adhesion are capable of capturing rare viable CTCs for early cancer detection and the 
monitoring of cancer therapy, single-cell gene analysis,64 and other purposes.
Biomimetic and Bio-Inspired Scaffolds for Tissue Engineering
Nanomaterials for tissue engineering involve a broad spectrum of nanoscale formulations 
and structures developed to mimic tissue complexity and to modulate cellular function to 
yield therapeutic benefits.
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The Xia group at the Georgia Institute of Technology and Emory University has been 
developing practical nanomaterials for medical applications. They use electrospun 
nanofibers in tissue engineering.65 Electrospinning has been widely explored to process 
polymeric materials into nanofibers with tunable and controllable compositions, diameters, 
porosities, and surface properties. Owing to its small feature size, high porosity, and large 
surface area, a nonwoven mat of electrospun fibers can serve as a superb scaffold that 
mimics the extracellular matrix (ECM), which is critical to cell attachment and spreading. 
The nanofibers themselves can also be functionalized through the encapsulation or 
attachment of bioactive species, such as ECM proteins, enzymes, and growth factors. In 
addition, the nanofibers can be readily assembled into a wide variety of arrays or 
hierarchical structures by manipulating their alignment, stacking, or folding. All these 
attributes make electrospinning a powerful tool for generating nanostructured materials for a 
broad range of biomedical applications, including controlled release, drug delivery, and 
tissue engineering. Xia highlighted the use of aligned nanofibers to control the 
differentiation of embryonic stem cells into different types of neural lineages and to guide 
the outgrowth of neurites for peripheral nerve repair.66 He also pointed out that nanofiber 
scaffolds could be designed for repairing injuries to the flexor tendon and the tendon-to-
bone insertion site;67 they could also be used as wound dressings for brain surgery.68
Karp from Brigham and Women’s Hospital suggests that different approaches are required 
for solving medical problems versus solving basic science problems. He asserts that one 
must develop design criteria relevant to solving the problem in animal models, while 
considering the multiple steps required to bring a technology from the laboratory to the 
clinic. One must think through scale-up, manufacturing, regulatory issues, and patent 
strategy and then impose these criteria to advance toward a potential solution. In particular, 
turning to nature for solutions can aid in the problem-solving process, recognizing that 
everything living has overcome challenges, and thus we are surrounded by solutions. 
Through elucidating mechanisms behind these solutions with state-of-the-art tools, he 
asserts that we can identify ideas to help overcome even the most challenging of problems. 
Karp has created tissue adhesives using inspiration from slugs and snails,69 spiny-headed 
worms,70 porcupine quills,71 and spider webs. One of the adhesive technologies led to the 
formation of a company, Gecko Biomedical (Paris, France), and is on track to be tested for 
vascular graft applications in humans in late 2015. Of note is that, in these developments, 
failure should be embraced as part of the problem-solving process and is likely a prerequisite 
to success. In this work, it was important to build highly functional and multi-disciplinary 
teams that know what resources are available in their environment and how to access them.
Teoh from Nanyang Technological University is interested in processing biomaterials in an 
environmentally friendly way.72,73 To this end, his group has unearthed a solvent-free 
approach known as cryomilling, where biomaterials are processed at near cryogenic 
temperatures. Polymer particle size reduction has been achieved due to the high-energy 
collision process, which occurs below the glass transition temperature. Particle sizes may be 
reduced to the nanoscale, where surface thermodynamics play critical roles in determining 
their behavior, particularly the interactions between two chemically distinct phases, as in the 
case of composite biomaterials. Notably, there is also a significant challenge in obtaining 
reproducible, well-distributed composites. They have demonstrated that a variety of 
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composite biomaterials that incorporate second phases, such as inorganic elements, trace 
elements, and even drugs, may be processed efficiently via cryomilling.73 This technique 
also addresses second phase distribution issues that plague many other processing 
techniques, such as solvent-casting, electrospinning, and melt extrusion.
FUTURE OUTLOOK
Tremendously exciting advances in nanomaterials-based medical treatments, from cancer 
therapies, diabetes administration, and vaccine development to molecular diagnostics, tissue 
repair, and regeneration, are both underway and yet to come. The confluence of 
nanomaterials and emerging biomedical science provides vast commercial opportunities. 
While fundamental science has been fueled with numerous innovations over the past decade, 
as evidenced by the number of nanomaterial-associated formulations and devices in clinical 
development, the number of marketed products is still small, compared to traditional 
medications. Remaining challenges include effectively improving efficacy, while minimizing 
potential concerns, through the rational design and thorough evaluation of nanomaterials.
In oncology nanomedicine, for example, the acceleration of the translation process relies 
profoundly on a thorough understanding of how nanocarriers interact with the physiological 
environment. In addition to general evaluations based on the enhanced permeability and 
retention effect, biodistribution, and clearance mechanisms, more precise details should be 
taken into account, such as how the particles pass through the tumor microenvironment and 
enter cells to reach active sites.74,75,76 Moreover, in designing stimuli-responsive or 
programmable nanocarriers,77,78 a current theme in nanomedicine, closer investigations of 
the dynamic relationships between the phase transitions of materials and the relevant 
gradients in the biological environment, such as pH, redox, glucose, ATP, and enzyme 
activity, should enable more precise targeting and release.79–82
Second, a major stumbling block in the translation of nanomaterials for biomedical 
applications is safety concerns, especially for invasive administration. On one hand, clinical 
use requires the careful, prolonged evaluation of the local and systemic toxicity of 
nanomaterials as well as their potential immunogenicity.83 On the other hand, there is an 
urgent need to invent and to tailor new materials with excellent biocompatibility. Ideas 
inspired by nature, mimicking the structures and composites of natural particles, including 
viruses, vesicles, and cells, have attracted increasing interest and brought promising 
outcomes.
Third, regarding the rational design of nanomaterials with specific physicochemical 
properties84 for clinical applications, it is important to set uniformity in preclinical trials. 
Variability in particle size, surface properties, and stability as well as differences in cell 
lines, tumor properties, therapeutic doses, and pharmacokinetics/pharmacodynamics 
analysis have prevented the systematic comparison of relevant nanomaterials and have been 
an impediment to creating design rules for optimizing a specific formulation or device.
Last but not least, the design, development, and ultimately commercialization of clinically 
used nanomaterials require seamless collaboration and commitment between a broad range 
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of research investigators, investors, and regulatory authorities. Key to these activities are 
platforms for fusing ideas to shepherd emerging technologies further along safe and effective 
pipelines.
Overall, given the progress that has been made so far, we are optimistic that nanomaterials-
based clinical development will continue to be exciting, with growing numbers of 
innovations as well as those currently garnering FDA approval entering the clinic soon. We 
hope the ideas and concepts presented in this Nano Focus will be useful in the development 
of “ideal” nanomaterials features, the expansion of design criteria, and the enlightenment of 
research opportunities for evolving the next generations of biomedical materials.85,86,87
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Figure 1. 
In vivo activity of immunomodulatory SNAs as cancer vaccines.
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Figure 2. 
Barriers to successful in vivo delivery of nucleic acids using nonviral vectors. Reprinted with 
permission from ref 19. Copyright 2014 Macmillan Publishers Ltd.
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Figure 3. 
Subconjunctival instillation of nanocarriers incorporating latanoprost lowers eye pressure in 
glaucoma patients for up to 3 months. Reproduced from ref 37. Copyright 2014 American 
Chemical Society.
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Figure 4. 
Schematic for the nanoparticle-based treatment of acne. Silica–gold nanoparticles are 
delivered into sebaceous glands using low-frequency ultrasound. Nanoparticles are then 
activated using near-infrared light to induce thermolysis. Reprinted with permission from ref 
45. Copyright 2015 Elsevier.
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Figure 5. 
Nanoneedle for the delivery of VEGF-165 to upregulate blood vessel formation in muscle. 
(A) Scanning electron microscope (SEM) micrographs showing the morphology of porous 
silicon nanoneedle arrays with pitches of 2 μm. Scale bars, 2 μm. (B) High-resolution SEM 
micrographs of nanoneedle tips showing the nanoneedles’ porous structure and the tunability 
of tip diameter from less than 100 nm to over 400 nm. Scale bars, 200 nm. (C) Intravital 
bright-field (top) and confocal (bottom) microscopy images of the vasculature of untreated 
(left) and hVEGF-165-treated muscles with either direct injection (center) or nanoinjection 
(right). The fluorescence signal originates from systemically injected FITC–dextran. Scale 
bars, bright-field 100 μm; confocal 50 μm. (D, E) Quantification of the fraction of 
fluorescent signal (dextran) (D) and the number of nodes in the vasculature per mm2 (E) 
within each field of view acquired for untreated control, intramuscular injection (IM) and 
nanoinjection. *p = 0.05, **p < 0.01, ***p < 0.001. Error bars represent the SD of the 
averages of five areas taken from three animals. Reprinted with permission of figure and 
caption text from ref 48. Copyright 2015 Macmillan Publishers Ltd.
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